Well Health Tech Stock Price, News & Analysis

WELL Health Technologies (TSX: WELL, OTCQX: WHTCF) has received a Management Cease Trade Order (MCTO) from the British Columbia Securities Commission following a delay in filing its Annual Filings for the year ended December 31, 2024. The MCTO restricts the CEO and CFO from trading company securities until the required documents are filed.

The Annual Filings include the company's annual information form, audited annual financial statements, and management's discussion and analysis. During this period, the company has committed not to issue or acquire securities from insiders or employees. The MCTO does not affect non-insider shareholders' ability to trade.

The company will provide bi-weekly default status reports and announce completion once the Annual Filings are submitted to SEDAR+.

WELL Health Technologies Corp. (WHTCF) has exercised its call option rights to acquire significant shares in HEALWELL AI Inc. The transaction occurred concurrent with HEALWELL's acquisition of Orion Health Holdings for approximately NZ$175 million on April 1, 2025.

Through the exercise of the Call Right, WELL acquired 30.8 million Subordinate Voting Shares and 30.8 million Multiple Voting Shares from HEALWELL's founding shareholders. Following the transaction, WELL now owns 97,473,161 HEALWELL Shares and 30,800,000 Multiple Voting Shares, representing approximately 37% of the economic interest and 69% of the voting rights in HEALWELL on a partially-diluted basis.

WELL Health Technologies Corp. (WHTCF) has announced its intention to exercise a call option to acquire shares in HEALWELL AI Inc. concurrent with HEALWELL's acquisition of Orion Health Holdings The call option allows WELL to purchase up to 30.8 million Subordinate Voting Shares and 30.8 million Multiple Voting Shares from HEALWELL's founding shareholders at $0.125 and $0.0001 per share respectively.

HEALWELL is set to acquire Orion Health for approximately NZ$175 million, with closing anticipated on April 1, 2025. Following the exercise of the call right and the Orion Health acquisition, WELL is expected to own approximately 37% of the economic interest and 69% of the voting rights in HEALWELL on a partially-diluted basis. WELL was previously approved as a control person of HEALWELL by shareholders and the Toronto Stock Exchange.

WELL Health Technologies (TSX: WELL, OTCQX: WHTCF) has reported record patient visits for fiscal year 2024, achieving 5.7 million total patient visits, representing a significant 32% year-over-year growth, with organic growth accounting for 30%.

The company's Canadian patient services business demonstrated exceptional performance, recording 3.125 million patient visits, marking a 35% year-over-year increase. The organic growth in Canadian operations was particularly strong at 32%, comprised of 26% same clinic sales growth and 6% absorption growth.

These preliminary operational results highlight WELL's success in leveraging its technology-enabled care model to drive strong organic growth across its enterprise, particularly in its Canadian Clinics division.

WELL Health Technologies (TSX: WELL, OTCQX: WHTCF) announces plans to acquire a majority controlling interest in HEALWELL AI concurrent with HEALWELL's proposed acquisition of Orion Health on April 1, 2025. Following the exercise of its call right, WELL will hold approximately 37% economic interest and 69% voting interest in HEALWELL on a non-diluted basis.

WELL has exercised all 20.3M share purchase warrants and converted all HEALWELL convertible debentures, acquiring 43.3M additional Class A shares. The company expects HEALWELL to contribute approximately $160 million in revenue with positive Adjusted EBITDA to WELL's consolidated financial statements over the next 12 months.

HEALWELL's acquisition of Orion Health, valued at approximately $175 million, will provide access to Orion's global customer base serving 150 million lives worldwide. Orion Health is expected to generate over $100 million in revenues mostly from subscription licenses and services with strong double-digit Adjusted EBITDA margins.

WELL Health Technologies (TSX: WELL, OTCQX: WHTCF) has announced a delay in filing its 2024 audited annual financial statements beyond the March 31, 2025 deadline. The delay stems from accounting implications related to its subsidiary Circle Medical Technologies, which is under investigation by the U.S. Attorney's Office regarding certain billing practices.

Circle Medical, which contributed a net loss of $1.1 million to WELL's consolidated net income of $16.6 million in 2023 and less than 2.7% to consolidated Adjusted EBITDA, received a request for voluntary production of documents in September 2024. WELL expects to file the required documents by April 15, 2025, and has applied for a management cease trade order during this period.

The company states that the resolution is not expected to materially affect its cash position and confirms it continues to seek strategic alternatives for Circle Medical.

WELL Health Technologies (TSX: WELL, OTCQX: WHTCF) reports significant growth in its Canadian operations as of March 4, 2025. The company has added 11 clinics to its Canadian network since February 1, 2025 (9 acquired, 2 absorbed), generating combined revenues of approximately $29 million with $2 million in EBITDA.

Key highlights include:

• 24% organic growth in Canadian clinics for 2024 (12% same-clinic revenue growth, 12% organic absorption)
• Record pipeline of ~70 public sector opportunities across Canada worth over $300 million
• 34 potential clinic acquisition opportunities generating $450 million in revenues

The company is benefiting from increased 'Buy Canadian' sentiment following new procurement policies, particularly in British Columbia, where Premier David Eby announced a ban on new U.S. procurement contracts in response to U.S. tariffs. WELL reports no exposure to these tariffs, with over 60% of its revenues, Adj. EBITDA, and cashflow generated in U.S. dollars.

WELL Health Technologies Corp. (TSX: WELL, OTCQX: WHTCF) has announced significant updates for its subsidiary WELLSTAR Technologies Corp. The company has appointed Sarah Xu as VP of Growth Operations and Frank Seiferth as VP of Product, both bringing extensive experience from companies like Google and BlueDot.

WELLSTAR has completed two strategic acquisitions: Microquest, a leading EMR provider serving 375 clinics and 1,600 providers in Alberta, and Bluebird iT, Canada's largest provider of IT solutions for outpatient healthcare clinics, supporting over 700 medical clinics and hospitals. WELL has acquired a 51% stake in Bluebird iT.

With these acquisitions, WELLSTAR now delivers technology solutions to over 40% of all physicians in Canada through its 330+ team members. The company offers solutions including provincially integrated EMRs, revenue optimization, patient engagement solutions, and AI-enabled automation tools.

WELL Health Technologies (TSX: WELL, OTCQX: WHTCF) has released performance metrics for its acquired Canadian clinics, showing strong ROIC figures of 41%, 24%, and 28% for clinics acquired in 2022, 2023, and 2024 respectively, with effective multiples of 2.0x, 2.3x, and 2.6x Adj. EBITDA.

The company's M&A pipeline includes 165 clinics generating over $440 million in annual revenue, with 19 signed LOIs representing approximately $50 million in revenue. Both pipelines maintain double-digit Adj. EBITDA margins.

WELL confirmed it has no exposure to U.S.-Canada tariffs as it doesn't engage in cross-border sales. Over 60% of its revenues, Adj. EBITDA and cashflow is generated in U.S. dollars through U.S.-based entities. The company maintains its long-term goal of reaching $4 billion in revenues from Canadian sources.